News

King’s all-cash proposal is said to represent a 37% premium over the closing price of Alpharma common stock on August 21, 2008, the last trading day prior to

The net proceeds to Abiomed from the offering were approximately $41.7 million, after deducting the underwriting discount and estimated offering expenses. Morgan Stanley & Co was the sole

The clinical trial was a Phase IIb, randomized, placebo-controlled study of ATI-7505 in patients with chronic idiopathic constipation conducted at 42 trial sites in five countries. Patients were

The non-small cell lung cancer (NSCLC) trial is a randomized, multi-center, open-label Phase II study to evaluate the efficacy and safety of HGS-ETR1 in combination with carboplatin and

Innutria is said to be a specific blend of naturally occurring nutrients designed to be added to foods or beverages. After many years of thorough, scientific study and

The product will be launched immediately in more than 20,000 retail outlets under the trademark Coldizin24, at a very low risk for Scandinavian Clinical Nutrition (SCN), and with

MDP 301 is a multi-national, randomized, double-blind, placebo-controlled Phase III trial designed to examine the safety and effectiveness of PRO 2000 in preventing HIV infection in women. The

The court had previously granted a joint request by the parties to stay all proceedings in the case, including the Markman claims construction hearing (previously scheduled for June

By combining the product offerings under one company name, Q Pharma expects to better leverage the variety of services offered within the three organizations and also pass along